193902-78-2

Basic information

• Product Name: 1-BOC-4-(5-NITRO-2-PYRIDYL)PIPERAZINE
• Synonyms: 1-tert-Butoxycarbonyl-4-(5-nitropyrid-2-yl)piperazine, 2-(4-Boc-1-piperazinyl)-5-nitropyridine;4-(5-nitro-pyridin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester;tert-Butyl 4-(5-nitropyridin-2-yl)piperazine-1-carboxylate;1-Boc-4-(5-nitro-2-pyridinyl)-piperazine
• CAS NO: 193902-78-2
• Molecular Formula: C₁₄H₂₀N₄O₄
• Molecular Weight: 308.34
• Mol File: 193902-78-2.mol

Chemical Properties

• Melting Point: 168-172 °C(lit.)
• Boiling Point: 468.7°C at 760 mmHg
• Flash Point: 237.3°C
• Appearance: /
• Density: 1.258g/cm³
• Vapor Pressure: 5.84E-09mmHg at 25°C
• Refractive Index: 1.562
• PKA: 4.38±0.29(Predicted)
• CAS DataBase Reference: 1-BOC-4-(5-NITRO-2-PYRIDYL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-(5-NITRO-2-PYRIDYL)PIPERAZINE(193902-78-2)
• EPA Substance Registry System: 1-BOC-4-(5-NITRO-2-PYRIDYL)PIPERAZINE(193902-78-2)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN 2811 6.1/PG 3
• WGK Germany: 3
• Hazardous Substances Data: 193902-78-2(Hazardous Substances Data)

Usage

Uses

1. Used in Pharmaceutical Industry:
1-BOC-4-(5-NITRO-2-PYRIDYL)PIPERAZINE is used as an intermediate compound for the synthesis of various pharmaceuticals. Its unique structure and functional groups make it a valuable building block in the development of new drugs, particularly those targeting the central nervous system.
2. Used in Chemical Research:
1-BOC-4-(5-NITRO-2-PYRIDYL)PIPERAZINE is used as a research compound in the field of organic chemistry. Its reactivity and functional groups allow chemists to explore new reaction pathways and develop novel synthetic methods.
3. Used in Material Science:
1-BOC-4-(5-NITRO-2-PYRIDYL)PIPERAZINE is used as a component in the development of new materials with specific properties. Its unique structure and functional groups can be utilized to create materials with tailored characteristics, such as improved stability or enhanced reactivity.
4. Used in Agrochemical Industry:
1-BOC-4-(5-NITRO-2-PYRIDYL)PIPERAZINE is used as a precursor in the synthesis of agrochemicals, such as pesticides and herbicides. Its functional groups can be modified to create compounds with increased efficacy and selectivity in controlling pests and weeds.

InChI:InChI=1/C14H20N4O4/c1-14(2,3)22-13(19)17-8-6-16(7-9-17)12-5-4-11(10-15-12)18(20)21/h4-5,10H,6-9H2,1-3H3

Upstream product

• 4487-59-6 2-bromo-5-nitropyridine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 4548-45-2 2-chloro-5-nitropyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 82205-58-1 1-(5-nitro-2-pyridinyl)piperazine 
• 24903-85-3 2-isopropoxy-5-nitropyridine 

Downstream Products

• 119285-07-3 4-(5-aminopyridin-2-yl)piperazine-1-carboxylic acid tert-butyl ester 
• 82205-58-1 1-(5-nitro-2-pyridinyl)piperazine 
• 1185319-62-3 1-(5-nitro-2-pyridinyl)piperazine hydrochloride 
• 1085841-68-4 2-phenyl-N-[6-piperazin-1-ylpyridin-3-yl]-5-trifluoromethyl-1,3-oxazole-4-carboxamide hydrochloride 
• 1085836-67-4 4-{5-[(2-phenyl-5-trifluoromethyloxazole-4-carbonyl)amino]pyridin-2-yl}piperazine-1-carboxylic acid tert-butyl ester 
• 1228004-07-6 4-(5-aminopyridin-2-yl)-N-(2-fluorophenyl)piperazine-1-carboxamide 
• 1228004-43-0 4-(5-nitropyridin-2-yl)-N-(2-fluorophenyl)piperazine-1-carboxamide 
• 1275991-20-2 N-(2-fluorophenyl)-4-(5-(3-methylbenzofuran-2-carboxamido)pyridin-2-yl)piperazine-1-carboxamide 
• 1331778-53-0 C₂₁H₂₆N₄O₄ 
• 1062298-91-2 1-(5-nitropyridin-2-yl)-4-(phenylcarbonyl)piperazine 
• 1343404-03-4 cyclohexyl(4-(5-nitropyridin-2-yl)piperazin-1-yl)methanone 
• 1343404-04-5 (4-fluorophenyl)(4-(5-nitropyridin-2-yl)piperazin-1-yl)methanone 
• 1088209-92-0 (4-methoxyphenyl)(4-(5-nitropyridin-2-yl)piperazin-1-yl)methanone 
• 1017143-28-0 6-[4-(phenylcarbonyl)piperazin-1-yl]pyridin-3-amine 

Relevant articles and documents

Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives

In this study, a series of 3-(3-pyridyl)-oxazolidone-5-methyl ester derivatives was synthesized and characterized by1H NMR,13C NMR, and LC-MS. The conducted screening antibacterial studies of the new 3-(3-pyridyl)-oxazolidone-5-methyl ester derivatives established that the methyl sulfonic acid esters have broad activity spectrum towards Staphylococcus aureus, Streptococcus pneu-moniae, Bacillus subtilis and Staphylococcus epidermidis. Among them, compound 12e has the most potent activity, with an MIC of 16 μg/mL against B.subtilis, and could reduce the instantaneous growth rate of bacteria. Furthermore, molecular docking studies were also simulated for compound 12e to predict the specific binding mode of this compound. In addition, anthelmintic activity of these compounds was also evaluated against adult Indian earthworms (Pheretima posthuman). The results showed that compound 11b had the best effect. These results above can provide experimental ref-erence for the development of novel antibacterial and anthelmintic drugs.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said che

SMALL MOLECULE INHIBITORS OF GALECTIN-3

The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. (Formula (I))

TARGETED PROTEIN DEGRADATION

This invention provides pharmaceutical protein degraders and E3 ubiquitin ligase binders for therapeutic applications as described further herein.

Seeking potent anti-tubercular agents: Design and synthesis of substituted-: N -(6-(4-(pyrazine-2-carbonyl)piperazine/homopiperazine-1-yl)pyridin-3-yl)benzamide derivatives as anti-tubercular agents

Pyrazinamide is an important first-line drug used in shortening TB therapy. In our current work, a series of novel substituted-N-(6-(4-(pyrazine-2-carbonyl)piperazine/homopiperazine-1-yl)pyridin-3-yl)benzamide derivatives were designed, synthesized, and evaluated for their anti-tubercular activity against Mycobacterium tuberculosis H37Ra. Among the tested compounds, five compounds (6a, 6e, 6h, 6j and 6k) from Series-I and one compound (7e) from Series-II exhibited significant activity against Mycobacterium tuberculosis H37Ra with 50% inhibitory concentrations (IC50) ranging from 1.35 to 2.18 μM. To evaluate the efficacy of these compounds, we examined their IC90 values. Five of the most active compounds were found to be more active with IC90s ranging from 3.73 to 4.00 μM and one compound (6e) showed an IC90 of 40.32 μM. Moreover, single crystals were developed for 6d, 6f and 6n. In addition, most active compounds were evaluated for their cytotoxicity on HEK-293 (human embryonic kidney) cells. Our results indicate that the compounds are nontoxic to human cells. The molecular interactions of the derivatised conjugates in docking studies reveal their suitability for further development.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

N-heteroarylsulfonamide derivative, and preparation and application of same

The invention provides an N-heteroarylsulfonamide derivative, and preparation and an application of same. The derivative includes pharmaceutically acceptable salts and solvates thereof; a test provesthat the N-heteroarylsulfonamide derivative allows specific combination and inhibit or reduce the activity of potassium pathway Kv1.3, so that the derivative can be used for treating autoimmune diseases, caused by abnormal activation of the potassium pathway Kv1.3, of human or animal. An inhibitor in the invention also includes a medicinal composition of the compound. The invention also provides amethod for preparing the compound. The derivative has the general formula as the specification.

5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION

This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.

METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.